PAM
SAGE

Paradigm Asset Management’s Sage Therapeutics SAGE Stock Holding History

Paradigm Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-900
Closed -$38.1K – 843
2015
Q3 		$38.1K Buy
+900
New +$55.5K 0.01% 693

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Paradigm Asset Management's SAGE Position: Q4 2015 in Review

Paradigm Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2015, closing a stake of 900 shares — an estimated $38.1K sold.

Paradigm Asset Management first reported a position in SAGE in Q3 2015 and held it in 1 quarter. The position peaked at $38.1K in Q3 2015. 137 funds tracked by Wall St. Rank hold SAGE as of Q4 2015.

  • Paradigm Asset Management reported no remaining Sage Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Paradigm Asset Management sold 900 Sage Therapeutics shares in Q4 2015, an estimated $38.1K.
  • Paradigm Asset Management first reported a position in Sage Therapeutics in Q3 2015 and held it in 1 quarter.
  • Paradigm Asset Management's Sage Therapeutics position peaked at $38.1K in Q3 2015.
  • 137 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2015.

Based on Paradigm Asset Management's 13F filing for Q4 2015, filed 5 Feb 2016.